BNT327
Dual PD-L1 × VEGF-A Antibody Pumitamig Delivers Strong Phase 2 Results in ES-SCLC
At WCLC 2025, pumitamig (BioNTech/BMS) demonstrated 76% ORR and 100% disease control in ES-SCLC, outperforming current PD-L1 monotherapies. The bispecific antibody combines checkpoint blockade and anti-angiogenesis for enhanced efficacy.